317 related articles for article (PubMed ID: 17724769)
21. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
22. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation.
Hsiao G; Chang CY; Shen MY; Chou DS; Tzeng SH; Chen TF; Sheu JR
J Agric Food Chem; 2005 Jun; 53(13):5179-86. PubMed ID: 15969494
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
24. Antiplatelet activity of epigallocatechin gallate is mediated by the inhibition of PLCgamma2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity.
Jin YR; Im JH; Park ES; Cho MR; Han XH; Lee JJ; Lim Y; Kim TJ; Yun YP
J Cardiovasc Pharmacol; 2008 Jan; 51(1):45-54. PubMed ID: 18209568
[TBL] [Abstract][Full Text] [Related]
25. The antiplatelet activity of Geiji-Bokryung-Hwan, Korean traditional formulation, is mediated through inhibition of phospholipase C and inhibition of TxB(2) synthetase activity.
Park WH; Kim KS; Kim KH; Kim DS; Kim CH
Int Immunopharmacol; 2003 Jul; 3(7):971-8. PubMed ID: 12810354
[TBL] [Abstract][Full Text] [Related]
26. Effects of mitoxantrone and bisantrene on platelet aggregation and prostaglandin/thromboxane biosynthesis in vitro.
Frank P; Novak RF
Anticancer Res; 1986; 6(5):941-7. PubMed ID: 3467648
[TBL] [Abstract][Full Text] [Related]
27. Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.
Manaster Y; Shenkman B; Rosenberg N; Savion N
Thromb Res; 2009 Sep; 124(4):477-82. PubMed ID: 19632706
[TBL] [Abstract][Full Text] [Related]
28. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation.
Hsiao G; Wang Y; Tzu NH; Fong TH; Shen MY; Lin KH; Chou DS; Sheu JR
J Lab Clin Med; 2005 Oct; 146(4):216-26. PubMed ID: 16194683
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Depin JC; Vigié A; Chavernac G; Rousselot C; Lardy C; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1203-7. PubMed ID: 7848332
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets.
Sheu JR; Kan YC; Hung WC; Ko WC; Yen MH
Thromb Res; 1997 Nov; 88(3):259-70. PubMed ID: 9526946
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet activity of carnosol is mediated by the inhibition of TXA2 receptor and cytosolic calcium mobilization.
Lee JJ; Jin YR; Lim Y; Hong JT; Kim TJ; Chung JH; Yun YP
Vascul Pharmacol; 2006 Sep; 45(3):148-53. PubMed ID: 16916624
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet mechanism of 2-chloro-3-(4-hexylphenyl)-amino-1,4-naphthoquinone (NQ304), an antithrombotic agent.
Zhang YH; Chung KH; Ryu CK; Lee YH; Kim TJ; Song YS; Hwang KA; Yun YP
Pharmacol Toxicol; 2001 Apr; 88(4):181-6. PubMed ID: 11322175
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationship studies on chalcone derivatives: potent inhibition of platelet aggregation.
Ko HH; Hsieh HK; Liu CT; Lin HC; Teng CM; Lin CN
J Pharm Pharmacol; 2004 Oct; 56(10):1333-7. PubMed ID: 15482650
[TBL] [Abstract][Full Text] [Related]
35. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers.
Gries A; Herr A; Motsch J; Holzmann A; Weimann J; Taut F; Erbe N; Bode C; Martin E
Thromb Haemost; 2000 Feb; 83(2):309-15. PubMed ID: 10739391
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
Wang WY; Hsieh PW; Wu YC; Wu CC
Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492
[TBL] [Abstract][Full Text] [Related]
37. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.
Philipose S; Konya V; Sreckovic I; Marsche G; Lippe IT; Peskar BA; Heinemann A; Schuligoi R
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2416-23. PubMed ID: 21071691
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets.
Sheu JR; Hsiao G; Chou PH; Shen MY; Chou DS
J Agric Food Chem; 2004 Jul; 52(14):4414-8. PubMed ID: 15237945
[TBL] [Abstract][Full Text] [Related]
39. The in vitro and in vivo pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403.
Katada J; Takiguchi Y; Muramatsu M; Fujiyoshi T; Uno I
Thromb Res; 1997 Oct; 88(1):27-40. PubMed ID: 9336871
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation.
Jin YR; Ryu CK; Moon CK; Cho MR; Yun YP
Pharmacology; 2004 Apr; 70(4):195-200. PubMed ID: 15001820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
